| Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain … R Garcia-Carbonero, J Capdevila, G Crespo-Herrero, JA Díaz-Pérez, ... Annals of oncology 21 (9), 1794-1803, 2010 | 530 | 2010 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 209 | 2023 |
| Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab C Gomez-Martin, JC Plaza, R Pazo-Cid, A Salud, F Pons, P Fonseca, ... Journal of Clinical Oncology 31 (35), 4445-4452, 2013 | 207 | 2013 |
| Nutritional support and parenteral nutrition in cancer patients: an expert consensus report JA Virizuela, M Camblor-Álvarez, LM Luengo-Pérez, E Grande, ... Clinical and translational oncology 20, 619-629, 2018 | 180 | 2018 |
| Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective … A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela Echaburu, ... Journal of Clinical Oncology 33 (5), 465-471, 2015 | 179 | 2015 |
| Clinical evaluation and optimal management of cancer cachexia A Tuca, P Jimenez-Fonseca, P Gascón Critical reviews in oncology/hematology 88 (3), 625-636, 2013 | 148 | 2013 |
| SEOM clinical guidelines on nutrition in cancer patients (2018) R de Las Peñas, M Majem, J Perez-Altozano, JA Virizuela, E Cancer, ... Clinical and translational oncology 21, 87-93, 2019 | 133 | 2019 |
| Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer G Aparicio Gallego, S Díaz Prado, P Jiménez Fonseca, ... Clinical and Translational Oncology 9, 694-702, 2007 | 93 | 2007 |
| Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry P Jiménez Fonseca, A Carmona-Bayonas, R Hernández, A Custodio, ... British journal of cancer 117 (6), 775-782, 2017 | 92 | 2017 |
| Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 Classification: real‐world data from the Spanish Tumor Registry (R‐GETNE) B Nuñez‐Valdovinos, A Carmona‐Bayonas, P Jimenez‐Fonseca, ... The oncologist 23 (4), 422-432, 2018 | 81 | 2018 |
| Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the … E Martin-Perez, J Capdevila, D Castellano, P Jimenez-Fonseca, ... Neuroendocrinology 98 (2), 156-168, 2013 | 76 | 2013 |
| The mediating role of spirituality (meaning, peace, faith) between psychological distress and mental adjustment in cancer patients P Jimenez-Fonseca, U Lorenzo-Seva, PJ Ferrando, A Carmona-Bayonas, ... Supportive Care in Cancer 26, 1411-1418, 2018 | 73 | 2018 |
| Chronic opioid therapy in long-term cancer survivors A Carmona-Bayonas, P Jiménez-Fonseca, E Castañón, ... Clinical and Translational Oncology 19, 236-250, 2017 | 72 | 2017 |
| Factors associated with anxiety and depression in cancer patients prior to initiating adjuvant therapy P Jimenez-Fonseca, C Calderón, R Hernández, T Ramón y Cajal, M Mut, ... Clinical and Translational Oncology 20, 1408-1415, 2018 | 68 | 2018 |
| A trial of Lopinavir–Ritonavir in Covid-19 P Dalerba, B Levin, JL Thompson N Engl J Med 382 (21), 2020 | 65 | 2020 |
| Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study C Font, A Carmona-Bayonas, C Beato, Ò Reig, A Sáez, ... European Respiratory Journal 49 (1), 2017 | 65 | 2017 |
| Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509) J Capdevila, N Fazio, C Lopez, A Teulé, JW Valle, S Tafuto, A Custodio, ... Journal of Clinical Oncology 39 (20), 2304-2312, 2021 | 64 | 2021 |
| Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study A Carmona-Bayonas, P Jimenez-Fonseca, A Lamarca, J Barriuso, ... Journal of Clinical Oncology 37 (28), 2571-2580, 2019 | 61 | 2019 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global … J Xu, K Kato, E Raymond, RA Hubner, Y Shu, Y Pan, SR Park, L Ping, ... The Lancet Oncology 24 (5), 483-495, 2023 | 60 | 2023 |
| 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic … J Capdevila, A Teule, C López, R García-Carbonero, M Benavent, ... Annals of Oncology 31, S770-S771, 2020 | 60 | 2020 |
